NASHVILLE, Tenn.--(BUSINESS WIRE)--A federal judge has ruled in favor of RyMed Technologies in a patent lawsuit filed by Vygon. U.S. District Judge Kevin Sharp of Tennessee federal court said RyMed’s InVision-Plus® IV connector did not and does not infringe upon Vygon's U.S. Patent #5,380,306 (known as “patent ‘306”).
The Vygon case originated in 2007 and resulted in opposing lawsuits between the two companies, plus a request from RyMed to the U.S. Patent and Trademark Office (USPTO).
RyMed asked the USPTO to reexamine the Vygon patent and hold that all but one of the claims of Vygon's patent were invalid. The remaining claim was not part of the reexamination.
After several years of review, the USPTO found in RyMed’s favor and held that Vygon’s claims were invalid. “Because the claims of the ‘306 Patent that are at issue in this case have been cancelled by the USPTO,” Judge Sharp decreed, “RyMed is entitled to judgment that the RyMed Connector Systems do not infringe on the ‘306 Patent.”
Judge Sharp’s decision ended the case in favor of RyMed and against Vygon, in line with the USPTO finding.
“The judge’s decision is further proof of the strength of RyMed’s intellectual property portfolio. This is also another validation of our products’ unique design and technology, and further strengthens our position in the very large global marketplace for our devices,” said Dana Wm. Ryan, President, CEO and Chairman of the Board of RyMed Technologies.
The Vygon case is the latest victory in a patent suit for RyMed Technologies. In May, a federal jury in Delaware found in favor of RyMed and against ICU Medical, ruling that RyMed’s InVision-Plus® with Neutral AdvantageTM technology products do not infringe on a patent held by ICU Medical.
About RyMed Technologies, Inc.
Founded in 1994, RyMed Technologies specializes in the development and marketing of innovative safety products in the field of intravenous catheter-care management. The company’s products are designed to help reduce catheter occlusion, catheter-related infections, and biofilm development commonly associated with vascular access devices. More than 10 years of research and development have gone into the InVision-Plus product line. Numerous studies regarding the efficacy of the InVision-Plus Needleless IV Connector have been published in the last six years — which is particularly important in light of the growing incidence of central line associated bloodstream infections (CLABSI).
For more information on the product and published studies, access www.rymedtech.com or call (615) 790-8093. The company is headquartered in Franklin, Tenn.